Nycomed to Market Roche Osteoporosis Drug in China and Asia-Pacific

Nycomed, the Swiss biopharma, will market a Roche osteoporosis treatment, Bonviva, in China and other Asia Pacific markets. Boniva, a bisphosphonate, will be added to Nycomed’s existing portfolio of osteoporosis products. Nycomed, the 28th largest biopharma in the world, generates the highest proportion of its revenues from developing companies of any large or medium-sized global pharma – an unusual metric – though China is not one of its top five markets. More details.... Stock Symbol: (VS: ROG)     Share this with colleagues: